Imunon, Inc.

Stocks

IMNN

US15117N7012

Market Closed - Nasdaq 16:00:00 2026-10-07 EDT			5-day change	1st Jan Change
1.140 ^USD	+1.79%		-11.63%	-70.08%

09-24	IMUNON, Inc. Presents Update On IMNN-001 Development Program For Women With Newly Diagnosed Advanced Ovarian Cancer	CI
09-23	Imunon, Inc. - Shareholder/Analyst Call

Transcript : Imunon, Inc. - Special Call

Published on 11/10/2025 at 05:05 pm EST

S&P Capital IQ

Presenter Speech
Stacy Lindborg (Executives)

All right. Good morning, everyone. I'm Stacy Lindborg. I'm the CEO of Imunon, and it is my true honor to get to welcome you to the 2025 Imunon R&D Day. As I

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Imunon, Inc.

09-24	IMUNON, Inc. Presents Update On IMNN-001 Development Program For Women With Newly Diagnosed Advanced Ovarian Cancer	CI
09-23	Imunon, Inc. - Shareholder/Analyst Call
09-22	IMUNON, Inc. Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development Of IMNN-001 Following Favorable Safety Review	CI
09-10	Imunon, Inc. Enters Cooperative Research and Development Agreement with National Cancer Institute	CI
08-26	IMUNON Hosts 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial And Clinical Potential Of IMNN-001	CI
08-11	Imunon, Inc., Q2 2026 Earnings Call, Aug 11, 2026
08-11	Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	IMUNON Reports Strong Enrollment Momentum In Phase 3 OVATION 3 Trial Of IMNN-001 In Advanced Ovarian Cancer	CI
07-30	Imunon Reports Enrollment Above Expectations in Phase 3 Trial of IMNN-001 to Treat Ovarian Cancer	MT
07-21	Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response	MT
06-30	Imunon, Inc. Appoints Josh Blacher as Principal Financial Officer and Principal Accounting Officer, Effective July 1, 2026	CI
06-30	Imunon, Inc. Announces Chief Financial Officer Changes, Effective July 1, 2026	CI
06-23	IMUNON Inc. Continues Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Chemotherapy	CI
06-23	Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue	MT
06-02	Imunon, Inc. announced that it has received $10 million in funding	CI

Chart Imunon, Inc.

Duration

Period

IMNN: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - Imunon, Inc.

More financial data

Ratings

More Ratings

EPS Estimates

Evolution of Analysts' Estimates - EPS - Imunon, Inc.

Revisions to estimates